Literature DB >> 447034

Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease.

T D Boyer, P Zia, T B Reynolds.   

Abstract

Renal function is known to be abnormal in patients with cirrhosis. Diminished cortical blood flow due to active renal vasoconstriction is present. Renal prostaglandins, potent vasodilators, could be released by the kidney in an attempt to maintain renal blood flow. This possibility was investigated by measuring the effect of indomethacin, an inhibitor of prostaglandin synthetase, in patients with alcoholic liver disease. Administration of indomethacin reduced the effective renal plasma flow (ERPF) and creatinine clearance by 23% and 19%, respectively (P less than 0.001), and increased serum creatinine by 29% (P less than 0.001). The response to indomethacin was variable (fall in ERPF (+)7.8% to (-)67%), but was greatest in patients with ascites. Eighty percent of ascitic patients had a greater than 15% fall in ERPF after administration of indomethacin compared with 20% of nonascitic patients (P less than 0.025). An infusion of prostaglandin A1 in 13 patients corrected the decrease in ERPF and creatinine clearance that had followed the administration of indomethacin. The administration of indomethacin caused a significant fall in plasma renin activity, 8.2 +/- 2.5 to 3.6 +/- 1.4 ng/ml/hr (P less than 0.025). The fall in plasma renin activity occurred when ERPF was depressed maximally, suggesting that endogenous prostaglandins exert more control over renin release than does ERPF. Prostaglandins appear to be an important factor in maintaining renal blood flow in patients with cirrhosis and sodium retention.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447034

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

2.  Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

Authors:  D Sacerdoti; M Balazy; P Angeli; A Gatta; J C McGiff
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Hepatorenal syndrome.

Authors:  Bimaljit Singh Sandhu; Arun J Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

Review 4.  The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure--a review.

Authors:  E S Domurat; A N Elias
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

Review 5.  Pathogenesis of ascites and hepatorenal syndrome.

Authors:  S P Wilkinson; K P Moore; V Arroyo
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

6.  Updates on Hepato-Renal Syndrome.

Authors:  Kyota Fukazawa; H Thomas Lee
Journal:  J Anesth Clin Res       Date:  2013-09-27

7.  Acute renal dysfunction in patients with alcoholic hepatitis.

Authors:  Robin Arora; Shweta Kathuria; Nishant Jalandhara
Journal:  World J Hepatol       Date:  2011-05-27

8.  Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

Authors:  Eric S Orman; Paul H Hayashi
Journal:  J Natl Cancer Inst       Date:  2013-04-16       Impact factor: 13.506

Review 9.  Effects of non-narcotic analgesics on the kidney.

Authors:  P Kincaid-Smith
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 10.  New clues to the pathophysiology of hepatorenal failure.

Authors:  F Lang; W Gerok; D Häussinger
Journal:  Clin Investig       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.